Sangamo Therapeutics, Inc. (SGMO): Price and Financial Metrics
GET POWR RATINGS... FREE!
SGMO POWR Grades
- Value is the dimension where SGMO ranks best; there it ranks ahead of 49.43% of US stocks.
- The strongest trend for SGMO is in Growth, which has been heading down over the past 179 days.
- SGMO's current lowest rank is in the Growth metric (where it is better than 13.48% of US stocks).
SGMO Stock Summary
- With a one year PEG ratio of 173.18, SANGAMO THERAPEUTICS INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 85.83% of US stocks.
- Of note is the ratio of SANGAMO THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; merely 8.73% of US stocks have a lower such ratio.
- The ratio of debt to operating expenses for SANGAMO THERAPEUTICS INC is higher than it is for about just 17.76% of US stocks.
- If you're looking for stocks that are quantitatively similar to SANGAMO THERAPEUTICS INC, a group of peers worth examining would be ALPN, TNGX, IDYA, GRTS, and BOLT.
- Visit SGMO's SEC page to see the company's official filings. To visit the company's web site, go to www.sangamo.com.
SGMO Valuation Summary
- In comparison to the median Healthcare stock, SGMO's price/sales ratio is 1.96% lower, now standing at 5.
- SGMO's EV/EBIT ratio has moved down 0.9 over the prior 243 months.
Below are key valuation metrics over time for SGMO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SGMO | 2023-01-30 | 5.0 | 1.8 | -3.1 | -2.8 |
| SGMO | 2023-01-27 | 5.2 | 1.9 | -3.3 | -3.0 |
| SGMO | 2023-01-26 | 5.0 | 1.8 | -3.2 | -2.9 |
| SGMO | 2023-01-25 | 5.1 | 1.8 | -3.2 | -2.9 |
| SGMO | 2023-01-24 | 5.0 | 1.8 | -3.2 | -2.9 |
| SGMO | 2023-01-23 | 5.0 | 1.8 | -3.2 | -2.9 |
SGMO Growth Metrics
- Its 4 year revenue growth rate is now at 469.27%.
- Its 5 year net income to common stockholders growth rate is now at -33.64%.
- Its 3 year price growth rate is now at -61.98%.
The table below shows SGMO's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 112.055 | -219.292 | -177.801 |
| 2022-06-30 | 114.158 | -225.094 | -172.334 |
| 2022-03-31 | 112.652 | -223.676 | -176.33 |
| 2021-12-31 | 110.701 | -233.251 | -178.286 |
| 2021-09-30 | 108.515 | -184.832 | -181.394 |
| 2021-06-30 | 137.715 | -92.345 | -135.256 |
SGMO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SGMO has a Quality Grade of C, ranking ahead of 46.27% of graded US stocks.
- SGMO's asset turnover comes in at 0.127 -- ranking 244th of 682 Pharmaceutical Products stocks.
- ALBO, LXRX, and ATNX are the stocks whose asset turnover ratios are most correlated with SGMO.
The table below shows SGMO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.127 | 1 | -0.356 |
| 2021-06-30 | 0.152 | 1 | -0.251 |
| 2021-03-31 | 0.143 | 1 | -0.252 |
| 2020-12-31 | 0.140 | 1 | -0.270 |
| 2020-09-30 | 0.191 | 1 | -0.186 |
| 2020-06-30 | 0.162 | 1 | -0.272 |
SGMO Price Target
For more insight on analysts targets of SGMO, see our SGMO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $20.67 | Average Broker Recommendation | 1.55 (Moderate Buy) |
SGMO Stock Price Chart Interactive Chart >
SGMO Price/Volume Stats
| Current price | $3.14 | 52-week high | $6.42 |
| Prev. close | $3.34 | 52-week low | $2.72 |
| Day low | $3.13 | Volume | 1,133,900 |
| Day high | $3.34 | Avg. volume | 1,146,188 |
| 50-day MA | $3.38 | Dividend yield | N/A |
| 200-day MA | $4.24 | Market Cap | 514.58M |
Sangamo Therapeutics, Inc. (SGMO) Company Bio
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focused on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for various monogenic and infectious diseases with unmet medical needs. The company was founded in 1995 and is based in Richmond, California.
Latest SGMO News From Around the Web
Below are the latest news stories about SANGAMO THERAPEUTICS INC that investors may wish to consider to help them evaluate SGMO as an investment opportunity.
7 CRISPR Stocks With the Best Long-Term PotentialCRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis. As a result, companies developing CRISPR-based products and services have seen significant valuation growth since inception, with many CRISPR stocks having excellent long-term upside potential in this regard. Several companies at the forefront of CRISPR technology have seen their stocks rise dramatically since going public. This can be attributed to the potential for CRISPR-based therapies to treat a wide range of genetic disorders and diseases, including cancer, sickle cell anemia, and cystic fibrosis. This technology also has potential applications for editing genes in animals... |
Sangamo Therapeutics Inc. (NASDAQ: SGMO)’s Stock Market Position Could Improve In The Coming MonthsIn the last trading session, 1.09 million shares of the Sangamo Therapeutics Inc. (NASDAQ:SGMO) were traded, and its beta was 1.08. Most recently the company’s share price was $3.57, and it changed around -$0.07 or -1.92% from the last close, which brings the market valuation of the company to $583.45M. SGMO currently trades at a … Sangamo Therapeutics Inc. (NASDAQ: SGMO)’s Stock Market Position Could Improve In The Coming Months Read More » |
Sangamo Therapeutics Inc. (SGMO) did well last session?As of Wednesday, Sangamo Therapeutics Inc.’s (NASDAQ:SGMO) stock closed at $3.33, up from $3.14 the previous day. While Sangamo Therapeutics Inc. has overperformed by 5.89%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SGMO fell by -57.48%, with highs and lows ranging from $7.99 to $2.72, […] |
There Are Mixed Signals on the Chart for Sangamo Therapeutics Inc. (SGMO)Sangamo Therapeutics Inc. (SGMO)’s stock is trading at $3.04 at the moment marking a rise of 9.35% from the last session close. As of this writing, shares are priced at -62.84% less than their 52-week high of $8.18, and 11.72% over their 52-week low of $2.72. Based on the past 30-day period, the stock price […] |
SGMO Stock: More Upside For Sangamo Therapeutics Inc. (NASDAQ: SGMO)?In the last trading session, 1.61 million Sangamo Therapeutics Inc. (NASDAQ:SGMO) shares changed hands as the company’s beta touched 1.13. With the company’s per share price at $3.10 changed hands at $0.01 or 0.32% during last session, the market valuation stood at $487.35M. SGMO’s last price was a discount, traded about -179.03% off its 52-week … SGMO Stock: More Upside For Sangamo Therapeutics Inc. (NASDAQ: SGMO)? Read More » |
SGMO Price Returns
| 1-mo | -6.82% |
| 3-mo | -22.08% |
| 6-mo | -50.39% |
| 1-year | -47.58% |
| 3-year | -59.33% |
| 5-year | -83.98% |
| YTD | 0.00% |
| 2022 | -58.13% |
| 2021 | -51.94% |
| 2020 | 86.44% |
| 2019 | -27.09% |
| 2018 | -30.00% |
Continue Researching SGMO
Want to see what other sources are saying about Sangamo Therapeutics Inc's financials and stock price? Try the links below:Sangamo Therapeutics Inc (SGMO) Stock Price | Nasdaq
Sangamo Therapeutics Inc (SGMO) Stock Quote, History and News - Yahoo Finance
Sangamo Therapeutics Inc (SGMO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...